BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP; TONES 3 Study Investigators. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial. Am J Respir Crit Care Med 2019;199:1421-31. [PMID: 30521757 DOI: 10.1164/rccm.201806-1100OC] [Cited by in Crossref: 54] [Cited by in F6Publishing: 68] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Singh H, Hyman D, Parks GS, Chen A, Foley C, Baldys B, Ito D, Thorpy MJ. Solriamfetol Titration and AdministRaTion (START) in Patients with Obstructive Sleep Apnea: A Retrospective Chart Review and Hypothetical Patient Scenario. Adv Ther 2022. [PMID: 35927541 DOI: 10.1007/s12325-022-02249-4] [Reference Citation Analysis]
2 Krystal AD, Benca RM, Rosenberg R, Schweitzer PK, Malhotra A, Babson K, Lee L, Bujanover S, Strohl KP. Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression. Journal of Psychiatric Research 2022. [DOI: 10.1016/j.jpsychires.2022.08.018] [Reference Citation Analysis]
3 Malhotra A, Strollo PJ, Pepin J, Schweitzer P, Lammers GJ, Hedner J, Redline S, Chen D, Chandler P, Bujanover S, Strohl K. Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy. Sleep Medicine 2022. [DOI: 10.1016/j.sleep.2022.08.005] [Reference Citation Analysis]
4 Amouzadeh-ghadikolai O, Popovic R, Heidbreder A, Kugi A, Saletu M. Konsensus-Statement der Österreichischen Gesellschaft für Schlafmedizin (ÖGSM/ASRA) zum Management der residualen exzessiven Tagesschläfrigkeit (rETS) bei obstruktiver Schlafapnoe: Die SPAIN-Checkliste für den klinischen Alltag. Somnologie. [DOI: 10.1007/s11818-022-00359-3] [Reference Citation Analysis]
5 Craig S, Pépin JL, Randerath W, Caussé C, Verbraecken J, Asin J, Barbé F, Bonsignore MR. Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view. Eur Respir Rev 2022;31:210230. [PMID: 35613742 DOI: 10.1183/16000617.0230-2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pataka A. ‘One Size Doesn’t Fit for All’: There Is a Need for Targeted Personalized Therapy in Obstructive Sleep Apnea Syndrome. JCM 2022;11:3595. [DOI: 10.3390/jcm11133595] [Reference Citation Analysis]
7 Mayer G. Residuale exzessive Tagesschläfrigkeit bei obstruktiver Schlafapnoe. Somnologie. [DOI: 10.1007/s11818-022-00354-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Vinckenbosch F, Asin J, de Vries N, Vonk PE, Donjacour CEHM, Lammers GJ, Overeem S, Janssen H, Wang G, Chen D, Carter LP, Zhou K, Vermeeren A, Ramaekers JG. Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea. Hum Psychopharmacol 2022;:e2845. [PMID: 35633275 DOI: 10.1002/hup.2845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Won C, Bogan RK, Doghramji K, Ojile J, Bujanover S, Hyman DL, Hewett KA, Thomas R. In-office communication about excessive daytime sleepiness associated with treated obstructive sleep apnea: insights from an ethnographic study of physician-patient visits. Sleep Science Practice 2022;6. [DOI: 10.1186/s41606-022-00072-y] [Reference Citation Analysis]
10 Arzt M. Schlafbezogene Atmungsstörungen – Update 2021. Somnologie. [DOI: 10.1007/s11818-022-00344-w] [Reference Citation Analysis]
11 Kallweit U, Pevernagie D, Lammers GJ. “Sleepiness” in obstructive sleep apnea: getting into deep water. Sleep Medicine 2022. [DOI: 10.1016/j.sleep.2022.02.015] [Reference Citation Analysis]
12 Arachchige MA, Steier J. Beyond Usual Care: A Multidisciplinary Approach Towards the Treatment of Obstructive Sleep Apnoea. Front Cardiovasc Med 2021;8:747495. [PMID: 35071340 DOI: 10.3389/fcvm.2021.747495] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 El-Solh AA, Rudraraju A, Pasrija D, Bui H. Pharmacotherapy of residual excessive sleepiness among continuous positive airway pressure (CPAP) treated patients with sleep apnea. Expert Opin Pharmacother 2022;:1-10. [PMID: 35045769 DOI: 10.1080/14656566.2022.2029408] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Krahn LE, Zee PC, Thorpy MJ. Current Understanding of Narcolepsy 1 and its Comorbidities: What Clinicians Need to Know. Adv Ther 2022;39:221-43. [PMID: 34894325 DOI: 10.1007/s12325-021-01992-4] [Reference Citation Analysis]
15 Randerath W, Verbraecken J, de Raaff CAL, Hedner J, Herkenrath S, Hohenhorst W, Jakob T, Marrone O, Marklund M, McNicholas WT, Morgan RL, Pepin JL, Schiza S, Skoetz N, Smyth D, Steier J, Tonia T, Trzepizur W, van Mechelen PH, Wijkstra P. European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea. Eur Respir Rev 2021;30:210200. [PMID: 34853097 DOI: 10.1183/16000617.0200-2021] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
16 Mehra R, Heinzer R, Castillo P. Current Management of Residual Excessive Daytime Sleepiness Due to Obstructive Sleep Apnea: Insights for Optimizing Patient Outcomes. Neurol Ther 2021;10:651-72. [PMID: 34658002 DOI: 10.1007/s40120-021-00289-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Nokes B, Lin E, McGuire WC, Malhotra A. Alternative Therapies for Obstructive Sleep Apnea. Am J Respir Crit Care Med 2021;204:986-8. [PMID: 34406909 DOI: 10.1164/rccm.202102-0359RR] [Reference Citation Analysis]
18 Guerdjikova AI, Romo-Nava F, Blom TJ, Mori N, McElroy SL. Study protocol and rationale for a randomized, placebo-controlled trial of solriamfetol to treat binge eating disorder. Contemp Clin Trials 2021;110:106587. [PMID: 34610482 DOI: 10.1016/j.cct.2021.106587] [Reference Citation Analysis]
19 Weaver TE, Pepin JL, Schwab R, Shapiro C, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo PJ, Mayer G, Sarmiento K, Baladi M, Bron M, Chandler P, Lee L, Malhotra A. Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. J Clin Sleep Med 2021;17:1995-2007. [PMID: 34606437 DOI: 10.5664/jcsm.9384] [Reference Citation Analysis]
20 Rosenberg R, Babson K, Menno D, Morris S, Baladi M, Hyman D, Black J. Test-retest reliability of the Epworth Sleepiness Scale in clinical trial settings. J Sleep Res 2021;:e13476. [PMID: 34545626 DOI: 10.1111/jsr.13476] [Reference Citation Analysis]
21 Zaccara G, Bartolini E, Tramacere L, Lattanzi S. Drugs for patients with epilepsy and excessive daytime sleepiness. Epilepsy Behav 2021;124:108311. [PMID: 34534876 DOI: 10.1016/j.yebeh.2021.108311] [Reference Citation Analysis]
22 Ragnoli B, Pochetti P, Raie A, Malerba M. Comorbid Insomnia and Obstructive Sleep Apnea (COMISA): Current Concepts of Patient Management. Int J Environ Res Public Health 2021;18:9248. [PMID: 34501836 DOI: 10.3390/ijerph18179248] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
23 Bonsignore MR, Pepin JL, Cibella F, Barbera CD, Marrone O, Verbraecken J, Saaresranta T, Basoglu OK, Trakada G, Bouloukaki I, McNicholas WT, Bailly S, Pataka A, Kvamme JA, Hein H, Mihaicuta S, Grote L, Fanfulla F; ESADA Study Group. Excessive Daytime Sleepiness in Obstructive Sleep Apnea Patients Treated With Continuous Positive Airway Pressure: Data From the European Sleep Apnea Database. Front Neurol 2021;12:690008. [PMID: 34434158 DOI: 10.3389/fneur.2021.690008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
24 Lal C, Weaver TE, Bae CJ, Strohl KP. Excessive Daytime Sleepiness in Obstructive Sleep Apnea. Mechanisms and Clinical Management. Ann Am Thorac Soc 2021;18:757-68. [PMID: 33621163 DOI: 10.1513/AnnalsATS.202006-696FR] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
25 Schweitzer PK, Strohl KP, Mayer G, Rosenberg R, Chandler P, Baladi M, Lee L, Malhotra A. Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy. J Clin Sleep Med 2021;17:659-68. [PMID: 33179591 DOI: 10.5664/jcsm.8992] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Weaver TE, Drake CL, Benes H, Stern T, Maynard J, Thein SG, Andry JM Sr, Hudson JD, Chen D, Carter LP, Bron M, Lee L, Black J, Bogan RK. Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial. Ann Am Thorac Soc 2020;17:998-1007. [PMID: 32353246 DOI: 10.1513/AnnalsATS.202002-136OC] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
27 Fietze I, Blum H, Grüger H, Käßner F, Maurer JT, Nilius G, Penzel T, Triché D, Arzt M. Diagnostik und Therapie der residualen Tagesschläfrigkeit bei Patienten mit therapierter obstruktiver Schlafapnoe. Somnologie 2021;25:99-109. [DOI: 10.1007/s11818-021-00305-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Malhotra A, Shapiro C, Pepin JL, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo PJ, Mayer G, Sarmiento K, Baladi M, Chandler P, Lee L, Schwab R. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. Sleep 2020;43:zsz220. [PMID: 31691827 DOI: 10.1093/sleep/zsz220] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 24.0] [Reference Citation Analysis]
29 Rosenberg R, Baladi M, Bron M. Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea. J Clin Sleep Med 2021;17:711-7. [PMID: 33226332 DOI: 10.5664/jcsm.9006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Schulz R. Schlafbezogene Atmungsstörungen. Somnologie 2021;25:65-76. [DOI: 10.1007/s11818-021-00302-y] [Reference Citation Analysis]
31 Abad VC. Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives. Nat Sci Sleep 2021;13:75-91. [PMID: 33531850 DOI: 10.2147/NSS.S245020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
32 Weaver TE, Menno DM, Bron M, Crosby RD, Morris S, Mathias SD. Determination of thresholds for minimally important difference and clinically important response on the functional outcomes of sleep questionnaire short version in adults with narcolepsy or obstructive sleep apnea. Sleep Breath 2021;25:1707-15. [PMID: 33394323 DOI: 10.1007/s11325-020-02270-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Weaver TE, Mathias SD, Crosby RD, Bron M, Bujanover S, Menno D, Villa KF, Drake C. Relationship between sleep efficacy endpoints and measures of functional status and health-related quality of life in participants with narcolepsy or obstructive sleep apnea treated for excessive daytime sleepiness. J Sleep Res 2021;30:e13210. [PMID: 33051943 DOI: 10.1111/jsr.13210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
34 Zomorodi K, Chen D, Lee L, Swearingen D, Carter LP. A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants. Clin Pharmacol Drug Dev 2021;10:404-13. [PMID: 32935460 DOI: 10.1002/cpdd.867] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Trotti LM, Arnulf I. Idiopathic Hypersomnia and Other Hypersomnia Syndromes. Neurotherapeutics 2021;18:20-31. [PMID: 32901432 DOI: 10.1007/s13311-020-00919-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
36 Dauvilliers Y, Verbraecken J, Partinen M, Hedner J, Saaresranta T, Georgiev O, Tiholov R, Lecomte I, Tamisier R, Lévy P, Scart-Gres C, Lecomte JM, Schwartz JC, Pépin JL; HAROSA II Study Group collaborators. Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial. Am J Respir Crit Care Med 2020;201:1135-45. [PMID: 31917607 DOI: 10.1164/rccm.201907-1284OC] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 15.0] [Reference Citation Analysis]
37 Trotti LM. Treat the Symptom, Not the Cause? Pitolisant for Sleepiness in Obstructive Sleep Apnea. Am J Respir Crit Care Med 2020;201:1033-5. [PMID: 31990205 DOI: 10.1164/rccm.202001-0104ED] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Malhotra RK. Pro-Con Debate: Use of Wake-Promoting Agents for the Treatment of Daytime Fatigue in OSA Patients with Curtailed CPAP Use (Less than 6 h). Curr Sleep Medicine Rep 2020;6:184-8. [DOI: 10.1007/s40675-020-00175-x] [Reference Citation Analysis]
39 Barker EC, Flygare J, Paruthi S, Sharkey KM. Living with Narcolepsy: Current Management Strategies, Future Prospects, and Overlooked Real-Life Concerns. Nat Sci Sleep 2020;12:453-66. [PMID: 32765142 DOI: 10.2147/NSS.S162762] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
40 Rameau A, Hong RS, Djalilian H, Erbele ID, Phillips KM, Capasso R, Rose AS, Brenner MJ, Santa Maria PL. New Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review of 2019. OTO Open 2020;4:2473974X20932506. [PMID: 32537556 DOI: 10.1177/2473974X20932506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
41 Powell J, Piszczatoski C, Garland S. Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea. Ann Pharmacother 2020;54:1016-20. [PMID: 32270686 DOI: 10.1177/1060028020915537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
42 Sunwoo BY, Schmickl CN, Malhotra A. Contemporary Concise Review 2019: Sleep and ventilation. Respirology 2020;25:552-8. [PMID: 32048407 DOI: 10.1111/resp.13781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Weaver TE. Novel Aspects of CPAP Treatment and Interventions to Improve CPAP Adherence. J Clin Med 2019;8:E2220. [PMID: 31888148 DOI: 10.3390/jcm8122220] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 5.7] [Reference Citation Analysis]
44 Sahni AS, Carlucci M, Malik M, Prasad B. Management Of Excessive Sleepiness In Patients With Narcolepsy And OSA: Current Challenges And Future Prospects. Nat Sci Sleep 2019;11:241-52. [PMID: 31695533 DOI: 10.2147/NSS.S218402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
45 Donovan LM, Shah A, Chai-Coetzer CL, Barbé F, Ayas NT, Kapur VK. Redesigning Care for OSA. Chest 2020;157:966-76. [PMID: 31639334 DOI: 10.1016/j.chest.2019.10.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
46 Kapur VK, Donovan LM. Taking Care of Persistent Sleepiness in Patients with Sleep Apnea. Am J Respir Crit Care Med 2019;199:1310-1. [PMID: 30589565 DOI: 10.1164/rccm.201812-2291ED] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
47 Zomorodi K, Chen D, Lee L, Lasseter K, Marbury T. Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. J Clin Pharmacol 2019;59:1120-9. [PMID: 30865315 DOI: 10.1002/jcph.1402] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]